The patient-derived xenograft, commonly called PDX, is based on direct implantation of a freshly harvested patient tumor fragment into immunocompromised mice. During successive transplants, the PDX will then stabilize and retain in most cases the genomic and phenotypic characteristics of the initial human tumor.
Tumor fragments from these PDXs can be cryopreserved after each successive transplantation for later reuse. PDXs offer a relevant approach to better understand the development of cancers in order to explore new therapeutic strategies
To learn more about our PDX offer, please contact us.